Risk assessment
Risk assessment and seroprevalence of SARS-CoV-2 infection in
healthcare workers of COVID-19 and non-COVID-19 hospitals
in Southern Switzerland
Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work.
Supplement to: Dagan N, Barda N, Kepten E, et al.
BNT162b2 mRNA Covid-19 vaccine in a nationwide mass
vaccination setting. N Engl J Med.
DOI: 10.1056/NEJMoa2101765
COVID_Impfung_mRNA Vaccine BNT162b2 Pfizer Mass Vaccination Israel Appendix Dagan et al NEJM 02 2021
BNT162b2 mRNA Covid-19 Vaccine
BNT162b2 mRNA Covid-19 Vaccine
in a Nationwide Mass Vaccination Setting
Noa Dagan, M.D., Noam Barda, M.D., Eldad Kepten, Ph.D., Oren Miron, M.A., Shay Perchik, M.A., Mark A. Katz, M.D., Miguel A. Hernán, M.D., Marc Lipsitch, D.Phil., Ben Reis, Ph.D., and Ran D. Balicer, M.D.
COVID_Impfung_mRNA Vaccine BNT162b2 Pfizer Mass Vaccination Israel Dagan et al NEJM 02 2021